

## Catherine Ledent

### Publications split in main topics of interest:

#### Thyroid physiology :

Identification of a cAMP-responsive region in thyroglobulin gene promoter, D. Christophe, C. Gérard, G. Juvenal, A. Bacolla, E. Teugels, **C. Ledent**, C. Christophe-Hobertus, J.E. Dumont and G. Vassart, *Mol. and Cel. Endocrinol.* 64 (1989), 5-18.

Tissue-specific expression and methylation of a thyroglobulin-CAT fusion gene in transgenic mice, **C. Ledent**, M. Parmentier and G. Vassart, *Proc. Natl. Acad. Sci. USA* 87 (1990), 6176-6180.

Thyroid adenocarcinomas secondary to tissue-specific expression of SV40 large T antigen in transgenic mice, **C. Ledent**, J.E. Dumont, G. Vassart and M. Parmentier, *Endocrinology* 129 (1991), 1391-1401.

Specific ablation of thyroid cells in adult transgenic mice, H. Wallace, **C. Ledent**, G. Vassart, J.O. Bishop and R. Al-Shawi, *Endocrinology* 129 (1991), 3217-3226.

Thyroid expression of an A<sub>2</sub> adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism, **C. Ledent**, Dumont J.E., Vassart G. and Parmentier M., *EMBO J.* 11 (1992), 537-542.

Models of thyroid goitre and tumours in transgenic mice, **C. Ledent**, M. Parmentier, G. Vassart and J.E. Dumont, *Mol. Cell. Endocrinol.* (1994) 100, 167-169.

Molecular genetics of thyroid diseases, **C. Ledent**, J. Parma, J.E. Dumont, G. Vassart and H. Targovnik, *Eur. J. Endocrinol.* (1994) 130, 7-14.

Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene, **C. Ledent**, A. Marcotte, J.E. Dumont, G. Vassart and M. Parmentier, *Oncogene* (1995) 10, 1789-1797.

Targeted expression of the *ret*/PTC1 oncogene induces papillary thyroid carcinomas, S.M. Jhiang, J.E. Sagartz, Q. Tong, J. Parker-Thornburg, C.C. Capen, J-Y Cho, S. Xing and **C. Ledent**, *Endocrinology* (1996) 137, 375-378.

Transgenic models for proliferative and hyperfunctional thyroid disease, **C. Ledent**, F. Coppée, G. Vassart, M. Parmentier, *Exp. Clin. Endocrinol. Diabetes* (1996) 104, 43-46.

Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter, P. Rochefort, B. Caillou, F-M. Michiels, **C. Ledent**, M. Talbot, M. Schlumberger, F. Lavelle, R. Monier and J. Feunteun, *Oncogene* (1996) 12, 111-118.

Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene, F. Coppée, A-C. Gérard, J-F. Deneff, **C. Ledent**, G. Vassart, J.E. Dumont and M. Parmentier, *Oncogene* (1996) 13, 1471-1482.

The cAMP in Thyroid, N. Uyttersprot, A. Allgeier, M. Baptist, D. Christophe, F. Coppée, K. Coulonval, S. Deleu, F. Depoortere, S. Dremier, F. Lamy, **C. Ledent**, C. Maenhout, F. Miot, V. Panneels, J. Parma, M. Parmentier, I. Pirson, V. Pohl, P. Roger, V. Savonet, M. Taton, M. Tonacchera, J. Van Sande, F. Wilkin, G. Vassart and J. E. Dumont, *Advances in second messenger and Phosphoprotein Research*, J. Corbin and S. Francis eds (1997) 31, 125-140.

Costimulation of adenylyl cyclase and phospholipase C by a mutant  $\alpha_{1B}$ -adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells, **C. Ledent**, J-F. Deneff, S.

Cotecchia, R. Lefkowitz, J. Dumont, G. Vassart and M. Parmentier, *Endocrinology* (1997) 138, 369-378.

Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours, F. Coppée, F. Depoortere, J. Bartek, **C. Ledent**, M. Parmentier and J. E. Dumont, *Oncogene* 17 (1998), 631-641.

Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice, G. Portella, C. Borselli, M. Santoro, D. Gerbasio, M.R. D'Armiento, J.E. Dumont, **C. Ledent**, J.L. Rothstein, G. Vecchio, A. Fusco, *Oncol Res* 12 (8) (2000), 347-54.

HMGI-C gene expression is not required for in vivo thyroid cell transformation, S. Scala, G. Portella, D. Vitagliano, **C. Ledent**, G. Chiappetta, V. Giancotti, J. Dumont, A. Fusco, *Carcinogenesis* 22(2) (2001), 251-256.

Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice, C.M. Gérard, N. Baudson, K. Kraemer, **C. Ledent**, D. Pardoll, C. Bruck, *Clin. Cancer Res.* 7 (3) (2001), 838s-847s.

The role of cAMP and its effect on protein kinase A in the mitogenic action of thyrotropin on the thyroid cell, S. Dremier, K. Coulonval, S. Perpete, F. Vandeput, N. Fortemaison, A. Van Keymeulen, S. Deleu, **C. Ledent**, S. Clément, S. Schurmans, J.E. Dumont, F. Lamy, PP. Roger and C. Maenhout, *Ann. N. Y. Acad. Sci.* 968 (2002), 106-121.

Relationships between cell division, expression of growth factors and microinjection in the thyroids of Tg-A2aR transgenic mice and patients with Graves' disease, A-C. Gérard, J-F. Denef, M-C. Many, P. Gathy, C. de Burbure, M-F van den Hove, F. Coppée, **C. Ledent** and I. M. Colin, *J. Endocrinol.* 177 (2003), 269-277.

Gene expression profile in thyroid of transgenic mice overexpressing the adenosine receptor 2a, J.C. Goffard, L. Jin, H. Mircescu, P. Van Hummelen, **C. Ledent**, J.E. Dumont, B. Corvilain, *Mol. Endocrinol.* 18 (1) (2004), 194-213.

## **G protein coupled receptors**

Cloning and characterization of G protein-coupled receptors, M. Parmentier, F. Libert, J. Perret, D. Eggerickx, **C. Ledent**, S. Schurmans, E. Raspe, J.E. Dumont and G. Vassart, *Advances in second messenger and phosphoprotein research*, P. Greengard, A. Robison, S. Shenolikar and A. Nairn eds (1992) 28, 11-18.

Members of the putative olfactory receptor gene family are expressed in mammalian germ cells, M. Parmentier, F. Libert, S. Schurmans, S. Schiffmann, A. Lefort, D. Eggerickx, **C. Ledent**, C. Mollereau, C. Gérard, J. Perret, A. Grootegoed and G. Vassart, *Nature* 355 (1992), 453-455.

### **- Adenosine A<sub>2a</sub> receptors :**

Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A<sub>2a</sub> receptor, **C. Ledent**, J-M. Vaugeois, S. Schiffmann, T. Pedrazzini, M. EL Yacoubi, J.-J. Vanderhaegen, J. Costentin, J. K. Heath, G. Vassart and M. Parmentier, *Nature* (1997) 388, 674-678.

Regulation of the phosphorylation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa *in vivo* by dopamine D<sub>1</sub>, dopamine D<sub>2</sub> and adenosine A<sub>2a</sub> receptors, P.S. Svenningsson, M. Lindskog, **C. Ledent**, M. Parmentier, P. Greengard, B.B. Fredholm and G. Fisone, *Proc. Natl. Acad. Sci. USA* 97 (2000), 1856-1860.

Regulation of nociceptin mRNA expression in the septum by dopamine and adenosine systems, D. Dassel, **C. Ledent**, J.C. Meunier, M. Parmentier and S.N. Schiffmann, *Neuroreport* 11(14) (2000), 3243-3246.

The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A<sub>2A</sub> adenosine receptor antagonists, M. El Yacoubi, **C. Ledent**, M. Parmentier, J. Costentin and J.-M. Vaugeois, *Psychopharmacology (Berl.)* 148 (2) (2000), 153-63.

The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A<sub>2A</sub> receptors, M. El Yacoubi, **C. Ledent**, J.-F. Ménard, M. Parmentier, J. Costentin and J.-M. Vaugeois, *Br. J. Pharmacol.* 129 (7) (2000), 1465-73.

SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: evidence for a functional 'atypical' adenosine A<sub>2A</sub> receptor, M. El Yacoubi, **C. Ledent**, M. Parmentier, J. Costentin and J.-M. Vaugeois, *Eur. J. Pharmacol.* 401 (1) (2000), 63-77.

Characterisation of central adenosine A<sub>1</sub> receptors and adenosine transporters in mice lacking the adenosine A<sub>2a</sub> receptor, B.J. Snell, J.L. Short, J. Drago, **C. Ledent**, A.J. Lawrence, *Brain Res.* 877(2) (2000), 160-169.

Visualisation of AMPA binding sites in the brain of mice lacking the adenosine A<sub>2a</sub> receptor, B.J. Snell, J.L. Short, J. Drago, **C. Ledent**, A.J. Lawrence, *Neurosci Lett.* 291(2) (2000), 97-100.

Absence of the adenosine A<sub>2a</sub> receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice, M. El Yacoubi, **C. Ledent**, M. Parmentier, M. Daoust, J. Costentin and J.M. Vaugeois, *Neuropharmacology* 40(3) (2001), 424-432.

Adenosine A<sub>2a</sub> receptor knockout mice are partially protected against drug-induced catalepsy, M. El Yacoubi, **C. Ledent**, M. Parmentier, J. Costentin and J.M. Vaugeois, *Neuroreport* 12 (5) (2001), 983-986.

Functional striatal hypodopaminergic activity in mice lacking adenosine A<sub>2A</sub> receptors. D. Dassel, A. Massie, R. Ferrari, **C. Ledent**, M. Parmentier, L. Arckens, M. Zoli and S.N. Schiffmann, *J. Neurochem.*, 78(1) (2001), 183-198.

G<sub>α</sub>olf levels are regulated by receptor usage and control dopamine and adenosine action in the striatum, D. Hervé, C. Lemoine, J.-C. Corvol, L. Belluscio, **C. Ledent**, A. A. Fienberg, M. Jaber, J.-M. Studler and J.-A. Girault, *J. Neurosci.*, 21 (12) (2001), 4390-4399.

Inactivation of A<sub>2a</sub> receptor impairs long term potentiation in the accumbens without altering basal synaptic transmission, P. D'Alcantara, **C. Ledent**, S. Swillens and S. N. Schiffmann, *Neuroscience* 107 (2001), 455-464.

Acute and chronic caffeine administration differentially alters striatal gene expression in wild-type and adenosine A<sub>2a</sub> receptor-deficient mice, D. Dassel, **C. Ledent**, M. Parmentier and S. N. Schiffmann, *Synapse* 42 (2) (2001), 63-76.

Cardiac effects of adenosine in A<sub>2a</sub> receptor knockout hearts: uncovering A<sub>2B</sub> receptors, R. R. Morrison, M.A.H. Talukder, **C. Ledent** and S.J. Mustapha, *Am. J. Physiol.* 282 (2002), H437-H444.

Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation, C. J. Van De Wiele, J.G. Vaughn, M.R. Blackburn, **C. Ledent**, M. Jacobson, H. Jiang, L. F. Thompson, *J. Clin. Invest.* 110 (3) (2002), 395-402.

Targeted deletion of adenosine A<sub>3</sub> receptors augments adenosine-induced coronary flow in isolated mouse heart, M.A. Talukder, R.R. Morrison, M.A. Jacobson, K.A. Jacobson, **C. Ledent**, S.J. Mustapha, *Am. J. Physiol. Heart Circ. Physiol.* 282 (6) (2002), H2183-9.

Relaxation of the mouse isolated aorta and carotid artery in response to adenosine analogues in genetically-modified mice lacking the adenosine A<sub>2a</sub> receptor, D.J. Prentice, M.D. Kelly, **C. Ledent**, S.M.O. Hourani, *Naunyn-Schmiedeberg's Arch Pharmacol* **366** (2002), 127-133.

Changes in spinal  $\delta$  and K opioid systems in mice deficient in the A<sub>2a</sub> receptor gene A. Bailey, **C. Ledent**, M. Kelly, S. Hourani and I. Kitchen, *J. Neurosci.* **22** (21), 9210-9220.

Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation, C. J. Van De Wiele, J.G. Vaughn, M.R. Blackburn, **C. Ledent**, M. Jacobson, H. Jiang, L. F. Thompson, *J. Clin. Invest.* **110** (3) (2002), 395-402.

Targeted deletion of adenosine A<sub>3</sub> receptors augments adenosine-induced coronary flow in isolated mouse heart, M.A. Talukder, R.R. Morrison, M.A. Jacobson, K.A. Jacobson, **C. Ledent**, S.J. Mustapha, *Am. J. Physiol. Heart Circ. Physiol.* **282** (6) (2002), H2183-9.

Relaxation of the mouse isolated aorta and carotid artery in response to adenosine analogues in genetically-modified mice lacking the adenosine A<sub>2a</sub> receptor, D.J. Prentice, M.D. Kelly, **C. Ledent**, S.M.O. Hourani, *Naunyn-Schmiedeberg's Arch Pharmacol* **366** (2002), 127-133.

Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A<sub>2A</sub> receptors, M. Naasila, **C. Ledent** and M. Daoust, *J. Neurosci.* **22** (23) (2002) 10487-93.

Aggravated brain damage after hypoxic ischemia in immature adenosine A<sub>2A</sub> knockout mice, U. Ådén, L. Halldner, H. Lagercrantz, I. Dalmau, **C. Ledent**, and B.B. Fredholm, *Stroke* **34** (2003), 739-744.

Increase of morphine withdrawal in mice lacking A<sub>2a</sub> receptors and no changes in CB<sub>1</sub>/A<sub>2a</sub> double knockout mice, F. Berrendero, A. Castané, **C. Ledent**, M. Parmentier, R. Maldonado and O. Valverde, *Eur. J. Neurosci.* **17** (2003), 315-324.

A dual role of Adenosine A<sub>2a</sub> receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A<sub>2a</sub> antagonists, D. Blum, M-C. Galas, A. Pintor, E. Brouillet, **C. Ledent**, C. E. Muller, K. Bantubungi, M ; Galluzzo, D. Gall, L. Cuvelier, A-S. Rolland, P. Popoli and S. Schiffmann, *J. Neurosci.* **23** (2003), 5361-5369.

Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A<sub>2a</sub> receptor, J.H. Wang, J. Short, **C. Ledent**, A.J. Lawrence and M. van den Buuse, *Behav. Brain Res.* **143** (2003), 201-207.

Caffeine reduces hypnotic effects of alcohol through adenosine A<sub>2A</sub> receptor blockade, M. El Yacoubi, **C. Ledent**, M. Parmentier, J. Costentin, JM. Vaugeois, *Neuropharmacology* **45** (7) (2003), 977-985.

A<sub>2a</sub> receptor and striatal cellular functions, S.N. Schiffmann, D. Dassel, P. d'Alcantara, **C. Ledent**, S. Swillens and Michele Zoli, *Neurology* **66** (Suppl 6), S24-S29.

Adenosine A<sub>2a</sub> receptor gene disruption provokes marked changes in melanocortin content and POMC gene expression, S. Jegou, M. El Yacoubi, L. Mounien, **C. Ledent**, M. Parmentier, J. Costentin, J. M. Vaugeois and H. Vaudry, *J. Neuroendocrinol.* **15** (12) (2003), 1171-1177.

Endogenous adenosine increases coronary flow by activation of both A<sub>2A</sub> and A<sub>2B</sub> receptors in mice, M.A. Talukder, R. Morrison, **C. Ledent** and S.J. Mustafa, *J. Cardiovasc. Pharmacol.* **41** (4) (2003), 562-570.

Enhanced morphine withdrawal and micro-opioid receptor G-protein coupling in A<sub>2A</sub> adenosine receptor knockout mice, Bailey A, Davis L, Lesscher HM, Kelly MD, **Ledent C**, Hourani SM, Kitchen I, *J. Neurochem.* **88** (4) (2004), 827-34.

Binding of the prototypical adenosine A2a receptor agonist, CGS 21680, to the cerebral cortex of adenosine A1 and A2a receptor knockout mice, L. V. Lopez, L. Halldner, N. Rebola, B. Johansson, **C. Ledent**, J.F. Chen, B. Fredholm and R. Cunha, *Br. J. Pharmacol.* (2004), 1-9.

The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion : a study in mice lacking A1 and / or A2A receptors, L. Halldner, U. Adén, V. Dahlberg, B. Johansson, **C. Ledent** and B.B. Fredholm, *Neuropharmacology* 46 (2004), 1008-1017.

[<sup>3</sup>H] Adenosine uptake in brainstem membranes of CD-1 mice lacking the Adenosine A<sub>2a</sub> receptor, B.J. Snell, A. Day, **C. Ledent**, A.J. Lawrence, *Life Sciences* 75 (2004), 225-235.

Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice – Evidence that CGS 21680 binds to A1 receptors in hippocampus, L. Halldner, L.V. Lopes, K. Lindström, B. Johansson, **C. Ledent**, R. A. Cunha and B. Fredholm *Naunyn Schmiedebergs Arch Pharmacol.* 370 (4) (2004), 270-8.

Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC, G. Soria, A. Castane, F. Berrendero, **C. Ledent**, M. Parmentier, R. Maldonado and O. Valverde, *Eur J Neurosci.* 20 (8) (2004) 2203-13.

Characterization of [3H]ZM 241385 binding in wild-type and adenosine A(2A) receptor knockout mice, M. Kelly, A. Bailey, **C. Ledent**, I. Kitchen, S.Hourani, *Eur J Pharmacol.* 504 (2004) 55-59

The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. I. Barna, D. Zelena, A.C. Arszovszki, **C. Ledent**, *Life Sci.* 75 (24) (2004) 2959-70.

Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis, A. Köfalvi, R. J. Rodrigues, **C. Ledent**, K. Mackie, E. S. Vizi, R. A. Cunha and B. Sperlágh, *J. Neurosci.* 25 (11) (2005) 2874-2884.

Potential of Neutrophil Cyclooxygenase-2 by Adenosine: An Early Anti-Inflammatory Signal. J-S Cadieux, P. Leclerc, M. St-Onge, A-A Dussault, C. Laflamme, S. Picard, **C. Ledent**, P. Borgeat and M. Pouliot *J. Cell Sci.* 118 (2005) 1437-1447.

Luminal adenosine stimulates chloride secretion through A1 receptor in mouse jejunum. E. Ghanem, C. Lovdahl, E. Dare, **C. Ledent**, B.B. Fredholm, J.M. Boeynaems, W. Van Driessche, R. Beauwens, *Am J Physiol Gastrointest Liver Physiol.* (2005). In press.

Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. G. Soria, V. Mendizabal, C. Tourino, P. Robledo, **C. Ledent**, M. Parmentier, R. Maldonado, O. Valverde *Neuropsychopharmacology* (2005) 1-11. In press.

## - Cannabinoid CB<sub>1</sub> receptor :

Unresponsiveness to Cannabinoids and Reduced Addictive Effects Of Opiates in CB1 Receptor Knock Out Mice, **C. Ledent**, O. Valverde, G. Cossu, F. Petitet, J.-F. Aubert, F. Beslot, A. Böhme, A. Imperato, T. Pedrazzini, B.P. Roques, G. Vassart, W. Fratta, M. Parmentier, *Science* (1999) 283, 401-404.

Enhancement of memory in cannabinoid CB<sub>1</sub> receptor knock-out mice, M. Reibaud, M. C. Obinu, **C. Ledent**, M. Parmentier, Georg A. Böhme, Assunta Imperato, *Eur. J. Pharmacol.* 379 (1) (1999), R1-R2.

Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB1 receptor knock-out mice, M.S. Mascia, M.C. Obinu, **C. Ledent**, M. Parmentier, G.A. Böhme, A. Imperato and W. Fratta, *Eur J Pharmacol* 383 (1999), R1-R2.

Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors, G. A. Böhme, M. Laville, **C. Ledent**, M. Parmentier, and A. Imperato, *Neuroscience* 95(1) (2000), 5-7.

Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors, O. Valverde, **C. Ledent**, F. Beslot, M. Parmentier, B.P. Roques, *Eur J Neurosci* 12 (2000), 533-539.

Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations, N. Hajos, I. Katona, S.S. Naiem, K. Mackie, **C. Ledent**, I. Mody and T.F. Freund, *Eur J Neurosci.* 12(9) (2000), 3239-3249.

Cocaine but not Morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice, M. Martin, **C. Ledent**, M. Parmentier, R. Maldonado and O. Valverde, *Eur J Neurosci.* 12(11) (2000), 4038-4046.

Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drug of abuse, G. Cossu, **C. Ledent**, L. Fattore, A. Imperato, G.A. Böhme, M. Parmentier, W. Fratta, *Behav. Brain Res.* 118(1) (2001), 61-65.

Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus, P. Derkinderen, **C. Ledent**, M. Parmentier, J.A. Girault, *J. Neurochem.* 77(3) (2001), 957-960.

The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. T. Wenger, **C. Ledent**, V. Csernus and Ida Gerendai, *Biochem. Biophys. Res. Commun.* 284 (2001), 363-368.

Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic transmission in the hippocampus, N. Hajos, **C. Ledent** and T.F. Freund, *Neuroscience* 106 (2001), 1-4.

Anandamide degradation and N-acylethanolamines level in wild-type and Cb1 cannabinoid knockout mice of different ages, M. Maccarone, M. Attinà, M. Bari, A. Cartoni, **C. Ledent** and A. Finazzi-Agro, *J. Neurochem.* 78 (2001), 339-348.

Metabotropic Glutamate receptors drive the endocannabinoid system in Hippocampus, N. Varma, G.C. Carlson, **C. Ledent** and B.E. Alger, *J. Neurosci.* 21 RC188 (2001), 1-5.

Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission, I. Katona, E.A. Rancz, L. Acsády, **C. Ledent**, K. Mackie, Norbert H. and T.F. Freund *J. Neurosci.* 21(23) (2001), 9506-9518.

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice K. Monory, E. T. Tzavara, J. Lexime, **C. Ledent**, M. Parmentier, A. Borsodi and J. Hanoune, *Biochem. Biophys. Res. Com.* 292 (2002), 231-235.

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors JW. Brooks, G. Pryce, T. Bisogno, S.I. Jagger, DJR Hankey, P. Brown, D. Bridges, **C. Ledent**, M. Bifulco, ASC. Rice, V. Di Marzo and D. Baker, *Eur. J. Pharmacol.* 439 (2002), 83-92.

Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour M. Maccarone, O. Valverde, M.L. Barbaccia, A. Castané, R. Maldonado, **C. Ledent**, M. Parmentier and A. Finazzi-Agro, *Eur. J. Neurosci.* 15 (2002), 1178-1186.

Involvement of CB1 cannabinoid receptors in emotional behaviour, M. Martin, **C. Ledent**, M. Parmentier, R. Maldonado, O. Valverde, *Psychopharmacology (Berl)* **159** (4) (2002), 379-87.

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice K. Monory, E. T. Tzavara, J. Lexime, **C. Ledent**, M. Parmentier, A. Borsodi and J. Hanoune, *Biochem. Biophys. Res. Com.* **292** (2002), 231-235.

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors JW. Brooks, G. Pryce, T. Bisogno, S.I. Jagger, DJR Hankey, P. Brown, D. Bridges, **C. Ledent**, M. Bifulco, ASC. Rice, V. Di Marzo and D. Baker, *Eur. J. Pharmacol.* **439** (2002), 83-92.

Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour M. Maccarone, O. Valverde, M.L. Barbaccia, A. Castané, R. Maldonado, **C. Ledent**, M. Parmentier and A. Finazzi-Agro, *Eur. J. Neurosci.* **15** (2002), 1178-1186.

Involvement of CB1 cannabinoid receptors in emotional behaviour, M. Martin, **C. Ledent**, M. Parmentier, R. Maldonado, O. Valverde, *Psychopharmacology (Berl)* **159** (4) (2002), 379-87.

Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence, A. Castane, E. Valjent, **C. Ledent**, M. Parmentier, R. Maldonado, O. Valverde, *Neuropharmacology* **43** (2002), 857-67.

The effect of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety, J. Haller, N. Bakos, M. Szirmay, **C. Ledent** and T.F. Freund, *Eur. J. Neurosci.* **16** (2002), 1395-1398.

Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus, J. Kim, M. Isokawa, **C. Ledent** and B.E. Alger, *J. Neurosci.* **22** (23) (2002), 10182-10191.

A role for endocannabinoids in indomethacin-induced spinal antinociception, H. Gühring, M. Hamza, M. Sergejeva, M. Ates, C.E. Kotalla, **C. Ledent** and K. Brune, *Eur. J. Pharmacol.* **454** (2002) 153-63.

Intrathecaly applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test, M. Ates, M. Hamza, K. Seidel, C.E. Kotalla, **C. Ledent** and H. Gühring, *Eur. J. Neurosci.* **17** (2003), 597-604.

Cannabinoids inhibit neurodegeneration in multiple sclerosis models, G. Pryce, Z. Ahmed, D.J.R. Hankey, S.J. Jackson, J.L. Croxford, J.M. Pocock, **C. Ledent**, B.F. Cravatt, A. Petzold, G. Giovannoni, M.L. Cuzner and D. Baker, *Brain* **126** (2003), 2191-2202.

Cannabinoids inhibit the release of (3H) glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action, A. Kofalvi, E.S. Vizi, **C. Ledent** and B. Sperlagh, *Eur. J. Neurosci.* **18** (7) (2003), 1973-1978.

The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice, T. Wenger, **C. Ledent** and G. Tramu, *Neuroendocrinology* **78** (6) (2003), 294-300.

Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus, P. Derkinderen, E. Valjent, M. Toutant, J-C. Corvol, H. Enslin, **C. Ledent**, J. Trzaskos, J. Caboche and J-A. Girault, *J. Neurosci.* **23** (6) (2003), 2371-2382.

Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice, M. Naasila, O. Pierrefiche, **C. Ledent** and M. Daoust, *Neuropharmacology* **46** (2) (2004), 243-253.

Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice, J. Haller, B. Varga, **C. Ledent**, I. Barna and T.F. Freund, *Eur. J. Neurosci.* 19 (2004), 1906-1912.

Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors, L. Urigüen, S. Pérez-Rial, **C. Ledent**, T. Palomo, J. Manzanares, *Neuropharmacology* 46 (2004) 966-973.

CB1 cannabinoid receptors mediate anxiolytic effects : convergent genetic and pharmacological evidence with CB1-specific agents, J. Haller, B. Varga, **C. Ledent** and T. F. Freund, *Behav Pharmacol* 15 (4) (2004) 299-304.

CB1 Receptor Knockout Mice Display Reduced Ethanol-Induced Conditioned Place Preference and Increased Striatal Dopamine D2 Receptors, H. Houchi, D. Babovic, O. Pierrefiche, **C. Ledent**, M. Daoust, M. Naassila M, *Neuropsychopharmacology* 30 (2) (2004), 339-49.

The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. I. Barna, D. Zelena, A.C. Arszovszki, **C. Ledent**, *Life Sci.* 75 (24) (2004) 2959-70.

Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis, A. Köfalvi, R. J. Rodrigues, **C. Ledent**, K. Mackie, E. S. Vizi, R. A. Cunha and B. Sperlág, *J. Neurosci.*

Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. G. Soria, V. Mendizabal, C. Tourino, P. Robledo, **C. Ledent**, M. Parmentier, R. Maldonado, O. Valverde *Neuropsychopharmacology* (2005) 1-11. In press.